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Abstract: The benefits of vitamin D derivatives for the treatment of chronic plaque psoriasis 
are well documented. Of importance is how compatible they are with, and how they compare to, 
other established treatments for psoriasis. This paper reviews 15 studies with calcitriol 3 µg g-1 
ointment (Silkis®/Vectical™ ointment; Galderma Laboratories) applied twice daily for up to 
52 weeks. The ointment was found to be effective and safe for the treatment of mild-to-moderate 
plaque psoriasis including sensitive skin areas. Calcitriol 3 µg g-1 ointment was found to be as 
effective as, or even superior to, other established treatment modalities and more highly tolerated 
than other local treatment modalities in most studies’ comparisons. It could be combined with 
other psoriasis treatment modalities such as ultraviolet B phototherapy or topical corticosteroids 
in order to achieve a faster response and in order to reduce the risk of adverse events.
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Introduction
Psoriasis is a chronic inflammatory disease of the skin which affects about 2% to 3% of 
the population. About 15% to 20% of these patients suffer from additional inflammatory 
diseases of their joints. Some authors state that psoriatic arthritis is more common in 
severe and advanced cases of skin psoriasis, but in up to 15% of cases it precedes the 
skin disease and about 6% never develop skin lesions. Psoriasis of finger or toe nail 
involvement is also observed in many cases. The most frequent clinical form of the 
skin disease is plaque psoriasis with lesions preferentially located on the scalp, elbows, 
knees and the sacral area. Established topical treatments of plaque psoriasis include 
salicylic acid, corticosteroids, dithranol, tar, and both vitamin A and D derivatives. 
In cases recalcitrant to topical therapy or extensive or with palmoplantar skin area 
involvement additional ultraviolet phototherapy or, alternatively, systemic treatment 
modalities including methotrexate, retinoids, cyclosporine, fumarates and biologics 
could be administered.
The overall effectiveness of topical vitamin D3 derivatives in treating psoriasis is 
well documented. Generally, patients show good tolerance to these agents, with no 
marked disturbance in their calcium metabolism,1,2 although hypercalcemia does occur 
occasionally3,4 and some patients reported skin irritations5,6 The important consideration 
for vitamin D derivatives now is their comparability and compatibility, both in terms 
of effectiveness and tolerance, with other established treatments for psoriasis.
An ointment with 3 µg g-1 calcitriol (Silkis®/Vectical™ ointment; Galderma 
Laboratories) was approved in Europe about 10 years ago and recently in the 
US for the treatment of mild-to-moderate plaque psoriasis. This paper reviews a Clinical, Cosmetic and Investigational Dermatology 2009:2 154
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number of studies in order to explore the characteristics 
of calcitriol and to establish its place in the armamen-
tarium available for the management of patients with 
psoriasis.
Pharmacology, mode of action,  
and pharmacokinetics
The role of calcitriol (1,25-dihydroxyvitamin D3), a naturally 
occurring endogenous hormonally-active derivative of 
vitamin D, in keratinocyte proliferation and differentiation, 
together with its effects on the immune response, are the reasons 
for the interest in its potential to control hyperproliferative, 
inflammatory skin diseases such as psoriasis. Receptors 
for calcitriol are found on epidermal keratinocytes and 
dermal fibroblasts.7 Furthermore, keratinocyte growth and 
differentiation are regulated by calcium concentration,8 and 
as calcitriol increases intracellular calcium concentration,9 
these processes may be indirectly affected by calcitriol. 
In vitro physiological studies have revealed that calcitriol 
inhibits the proliferation of human skin cells and induces 
them to differentiate into squamous and denucleated horny 
cells.10,11 Additionally, calcitriol enhances the expression 
of keratins K10 and K6 in the keratinocyte population in 
psoriasis plaques in vivo, which correlates with their clinical 
improvement.12 Furthermore, it has been shown that calcitriol 
acts as an immunomodulator in the skin as a potent inhibitor 
of T-cell proliferation and of several inflammatory mediators 
including interleukins-1, -6, and -8.13,14
In preclinical and phase I to III studies it was demonstrated 
that 3 µg g-1 calcitriol ointment is the minimal optimal effective 
dose for treatment of psoriasis, had no systemic toxicity and 
was tolerated well in the locality of application.15
In humans, following topical administration of 3 µg g-1 
calcitriol ointment to about 15% of the body surface area 
for 12 hours, on average 7.5% of the calcitriol applied was 
excreted mainly via feces over a 10-day period. The level of 
serum calcitriol remained unchanged and traces of exogenous 
calcitriol were only detected in 25% of participants in the 
relevant study.15 The main concern about the use of vitamin D 
derivatives is their possible influence on calcium homeostasis. 
In animals treated with 3 µg g-1 calcitriol ointment (on 15% 
of the body surface for four consecutive days) no increase in 
the urine calcium excretion could be observed as compared to 
animals treated with the excipient over 10 days.16 For health 
and safety reasons, in Europe, the use of 3 µg g-1 calcitriol 
ointment is only approved for treatment of up to 35% of the 
body surface area in psoriasis patients with a maximum of 
30 g per day being the approved level in the US. No irritant, 
sensitizing, phototoxic or photoallergic potential of 3 µg g-1 
calcitriol ointment could be detected in animal and human 
phase I studies.15
Clinical studies – general 
methodology
Several separate studies designed to asses the efficacy, 
tolerability, and safety of applying calcitriol 3 µg g-1 ointment 
twice a day are reviewed here; two were comparisons 
with an excipient, two were comparisons with other 
standard treatments for psoriasis, two were comparisons 
with calcipotriol, another vitamin D derivative, one was a 
comparison with tacrolimus, a drug not yet approved for 
psoriasis, four investigated the combination of calcitriol 
with other therapies, and four were open, uncontrolled 
investigations. Most of these studies have been reported in 
detail elsewhere.17–28
All studies were conducted with adult patients of both 
sexes with chronic plaque-type psoriasis. Unless otherwise 
specified, treatments were applied to all psoriatic lesions 
(except the head) for the duration of the study or until the 
lesions cleared up. Efficacy was mostly assessed in terms of 
global improvement, with erythema, scaling, induration and 
pruritus being scored according to the scale of Fredriksson 
and colleagues29 or global severity scores (GSS), physician’s 
global assessment scores (PGA), and dermatological 
sum scores (DSS). In many studies the psoriasis area and 
severity index (PASI) score was used as a secondary efficacy 
variable.30 In studies directed to treatment of special sensitive 
skin areas modified PASI or target area scores (TAS) were 
employed. Some studies included an evaluation of patients’ 
quality of life during treatment using the psoriasis disability 
index (PDI) or quality of life (QOL) questionnaires about 
daily activities.31,32
Evaluations were performed at the beginning of each 
study, at regular intervals throughout the relevant study, and at 
the end of each study. Blood chemistry parameters, including 
serum albumin, total and adjusted calcium, urea, phosphate, 
alkaline phosphatase, and creatinine were also measured at 
assessment points in most studies.
Efficacy, safety, and patient 
acceptance
Comparison with excipient
In two placebo-controlled multicenter randomized double-
blind parallel group studies including 839 subjects, 3 µg g-1 
calcitriol ointment or its excipient was administered twice Clinical, Cosmetic and Investigational Dermatology 2009:2 155
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daily for up to eight weeks. In both studies the drug was 
shown to be significantly more effective (P = 0.005 and 
P  0.001, respectively) according to the response rate, and 
both according to GSS and DSS (P  0.01 to P  0.001, 
respectively) in mild-to-moderate plaque psoriasis than its 
excipient. Furthermore, itching was significantly reduced 
in the calcitriol-treated group in both studies (P  0.001). 
In both studies calcitriol ointment had no effect on calcium 
homeostasis as well demonstrating a good systemic and 
local safety profile in comparison to the groups being treated 
with the excipient. There was a higher occurrence of local 
adverse events in the relevant locality where the excipient 
was applied.20
Comparison with short-contact dithranol
In an open, parallel-group study patients were randomized to 
eight weeks’ treatment with either calcitriol 3 µg g-1 ointment 
applied twice daily or dithranol cream applied once daily. 
Dithranol cream had to be removed after 30 min by shower 
bath. Its concentration started at 0.25% for the first seven days, 
and then increased to 0%, 1%, and 2% at seven-day intervals 
according to local tolerance. The global improvement scores 
and PASI scores were very similar between the two treatments; 
considerable or definite improvement, or total clearance of 
lesions, was observed in 72% of 60 calcitriol-treated patients 
and 70% of 54 dithranol-treated patients, respectively. At the 
end of the study the improvements measured against the 
start of the study in the PASI scores were 64% and 57%, 
respectively. In addition to standard assessments, the effect of 
psoriasis on the patients’ quality of life was measured using 
the PDI questionnaire about daily activities. Patients were 
also asked to assess the acceptability of the two medications 
in terms of staining, smell, ease of spreading and irritation. 
Patients in the calcitriol group experienced a significantly 
higher quality of life during the study period, than those in 
the dithranol group (P  0.05) as determined using the PDI 
questionnaire. There was also a significant difference in favor 
of calcitriol ointment in the rating of staining and irritation 
(P  0.01) and a higher proportion in the calcitriol group 
rated the overall acceptability of treatment as good (47%) 
than in the dithranol group (20%).18
Comparison with corticosteroid
In a randomized multicenter trial with 258 patients 
with chronic plaque psoriasis either calcitriol 3 µg g-1 
ointment or the topical corticosteroid betamethasone 
dipropionate were administered twice daily for six weeks. 
Global improvement and global severity scores at treatment 
endpoint showed statistically significant (P  0.05) 
differences in favor of betamethasone dipropionate, 
however the absolute reduction in mean PASI was 
comparable between the groups. A significantly (P  0.01) 
higher proportion of patients who responded remained 
in remission during the eight-week observation period 
following the calcitriol treatment (48%) as compared to 
the betamethasone treatment (25%). Seven patients in 
each treatment group reported local skin irritations. Two 
patients treated with calcitriol exhibited slight, transient 
asymptomatic hypercalcemia, whereas this observation was 
made in three cases of the betamethasone treated group. 
Patients’ overall opinion of both ointments was generally 
“good” or “acceptable” in 91% of the calcitriol and in 92% 
of the betamethasone group, respectively.22
Comparison with calcipotriol
To compare the efficacy and safety of calcitriol 3 µg g-1 
ointment and calcipotriol 50 µg g-1 ointment both were 
applied twice a day for 12 weeks, a multicenter, randomized 
investigator-blind parallel group study including 250 patients 
with mild-to-moderate plaque type psoriasis was performed. 
At endpoint the mean score of global improvement (0 = no 
change or worsening, 3 = cleared or almost cleared) rated by 
the physician was 2.27 for calcitriol and 2.22 for calcipitriol; 
such differences being statistically insignificant. The same 
parameter scored by the patients was 2.12 for calcitriol and 
2.09 for calcipotriol; again showing statistically insignificant 
differences. Mild to moderate skin irritation was observed 
in percent of the patients treated with calcitriol and in 11% 
treated with calcipotriol. The mean worst score for the 
cutaneous safety assessment (0 = none, 4 = very severe) was 
lower in the calcitriol group (0.1) compared to the calcipotriol 
group (0.3) according to the physician’s judgment. This 
difference was significant (P  0.005) in favor of a better 
cutaneous safety profile for calcitriol. According to the 
patients’ judgment, the mean worst score for the cutaneous 
discomfort was lower in the calcitriol group (0.2) compared 
to the calcipotriol group (0.4). This difference was significant 
(P  0.05) in favor of a better acceptance for calcitriol.24
In another intra-individual, randomized, investigator-
blinded left-right comparison study including 75 patients 
with symmetrical mild-to-moderate plaque psoriasis 
affecting sensitive areas (face, hairline, retroauricular and 
flexural areas) calcitriol 3 µg g-1 ointment was compared 
to calcipotriol 50 µg g-1 ointment both administered twice 
daily. Global assessment of improvements as compared to the 
beginning of the study by the investigators was significantly Clinical, Cosmetic and Investigational Dermatology 2009:2 156
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better for the calcitriol treated lesions and the subjects’ 
global preference was in favor of calcitriol (both P  0.05). 
Perilesional erythema, edema and stinging or burning were 
statistically significantly (P  0.05 to 0.001) less severe with 
calcitriol compared to calcipotriol. The patients’ evaluation of 
local tolerability in this study was significantly (P  0.0001) 
in favor of calcitriol, whereas there was no patient preference 
regarding both treatments according to efficacy.25
Comparison with tacrolimus
To compare the efficacy of calcitriol 3 µg g-1 ointment and of 
the calcineurin antagonist tacrolimus in a 300 µg g-1 ointment 
either given twice daily for six weeks, a double-blind parallel 
group study was performed including 50 patients with 
chronic plaque psoriasis involving facial and genitofemoral 
areas. At the end of the study significantly (P  0.05) more 
patients treated with tacrolimus (60%) achieved complete 
or almost complete clearance according physicians global 
assessment compared to calcitriol (33%). The same was true 
for a target area score which at the end of treatment decreased 
by 52% with calcitriol and 64% with tacrolimus, respectively. 
After two weeks, both calcitriol (71%) and tacrolimus (48%) 
induced considerable rates (nonsignificant) of perilesional 
erythema. After six weeks, calcitriol induced a statistically 
significant (P  0.005) higher rate (58%) compared to 
tacrolimus (16%). Nonsignificant differences were found for 
edema, stinging/burning, and hot sensations, which occurred 
in very few cases. In regard to overall tolerance, both treat-
ments were judged as excellent by 92% of the patients.27
Combinations with ultraviolet B 
phototherapy
The efficacy of calcitriol 3 µg g-1 ointment in combination 
with ultraviolet (UV) B phototherapy was compared with 
phototherapy alone in an eight-week study.19 The research 
was a double-blind study done through the use of vehicle 
ointment in the control group. Patients received three sessions 
per week of broad-band UVB phototherapy until endpoint; 
dosage followed a defined schedule depending on the patient’s 
skin type. The dose of UVB was reduced or interrupted as 
necessary in cases of local intolerance. Ointments were 
applied after irradiation or at least six hours beforehand. The 
treatment groups were comparable at the start of the study; 
the mean PASI scores of 17.4 for 49 patients in the calcitriol 
group and 16.6 for 53 patients in the control group were not 
significantly different. Mean global improvement scores 
increased throughout the study period, with the difference 
between treatments in favor of calcitriol plus UVB therapy 
being significant (P  0.05) in all but one of the time points 
starting from week 1. This clinical response was reflected 
in a highly significant difference (P = 0.005) in the mean 
percentage reduction in PASI score for patients treated with 
calcitriol plus UVB (65%) compared with those receiving 
phototherapy alone (43%). By study endpoint considerable 
or definite improvement or clearance of lesions was seen in 
45% of patients treated with calcitriol plus UVB and in 20% 
of those receiving UVB alone. The mean cumulative UVB 
dose was 5,291 J cm-2 in the calcitriol and 8,668 J cm-2 in 
the excipient group, respectively. Thus, on average, a 34% 
lower dose of UVB was administered to calcitriol-treated 
patients than to those in the control group.
In another open intra-individual half-side manner study, 
ten patients with symmetrical plaque psoriasis were treated 
on one arm with calcitriol 3 µg g-1 ointment twice daily 
and on the other arm with dithranol ointment once daily. 
Additionally, these patients received narrow-band (311 nm) 
UVB phototherapy five times a week for at least four weeks. 
Both treatment modalities notably reduced the modified 
PASI score equally effectively. Three patients preferred 
calcitriol rather than dithranol and one patient vice versa 
when both quality of life and treatment acceptability were 
assessed.21
Combinations with corticosteroids
In a small, double-blind, randomized study patients applied 
either the potent topical corticosteroid betamethasone 
valerate 0.1% ointment in the morning and calcitriol 
3 µg g-1 ointment in the evening (n = 9), or betamethasone 
valerate ointment in both the morning and the evening 
(n = 10). Treatment lasted for six weeks.33 The combination 
therapy was at least as effective as betamethasone alone, 
as indicated by the three measures of efficacy that were 
assessed. At study endpoint 78% of patients using calcitriol/
betamethasone and 60% of those using betamethasone daily 
showed considerable improvement, or better, according to 
the mean global improvement score. Likewise, the global 
severity score at endpoint was 1 (slight) for 78% of the 
combination group and 50% of the betamethasone group. 
Finally, the mean PASI score for patients in the calcitriol/
betamethasone group decreased over the course of the 
study by 81% compared to 75% for betamethasone-treated 
patients. No statistical analyses were performed due to the 
small population size.
In another two-phase parallel-group study including 
125 patients with chronic plaque type psoriasis either 
calcitriol 3 µg g-1 ointment or calcipotriol 50 µg g-1 Clinical, Cosmetic and Investigational Dermatology 2009:2 157
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ointment were administered in the morning and the topical 
corticosteroid clobetasol in the evening for two weeks, 
followed by monotherapy with either calcitriol or calcipotriol 
twice daily for another 10 weeks. At week 2 in both arms, 
more than 50% of the patients showed at least a marked 
improvement of their psoriasis and at week 12, 79% in the 
calcitriol and 88% in the calcipotriol group, respectively. 
Least-square means analysis of the PASI indicated both 
regimens to be equivalent. There were no differences between 
the groups with regards to cutaneous safety or to incidence 
of adverse effects.23
Open studies
In three separate studies, calcitriol 3 µg g-1 ointment was 
used to treat moderate or severe lesions of chronic plaque 
psoriasis localized in sensitive skin areas. In an open, 
five-center study, treatment was applied for eight weeks by 
11 male and 20 female patients with a history of psoriasis 
lasting from one to 757 months (mean 198 months) 
involving the face, hairline, or retroauricular areas.34 
A good response to treatment, in terms of improvement 
in scaling, erythema, induration, and pruritus, was seen 
by week 4 which continued through to week 8. The global 
improvement score indicated that at study endpoint, 74% 
of patients were classified as definitely improved, or better. 
Another group of patients (12 males, 8 females) applied 
calcitriol 3 µg g-1 ointment for 6 weeks to psoriatic plaques 
on the face, hairline or retroauricular areas in a single-center 
study.17 The clinical outcome showed a similar pattern 
to the previous study, although a higher proportion of 
patients experienced clearing of their lesions.17 One patient 
discontinued therapy prematurely, after 33 days of twice-
daily applications, due to complete clearance of lesions. 
In these two studies the cosmetic acceptability of treatment 
was judged as good by the vast majority of patients; only 
one patient considered the medication to be cosmetically 
unacceptable.
In another study 60 patients with mild-to-moderate 
plaque psoriasis involving sensitive areas were treated with 
calcitriol 3 µg g-1 ointment twice a day for 12 weeks. The 
clinical remission rate progressively increased throughout 
therapy from 11.6% at week 4 to 63.3% at week 12. No 
serious adverse events and clinically relevant changes of 
calcium homeostasis were observed. Six patients withdrew 
after four weeks of treatment because of increasing pruritus. 
Another 12 patients noted mild skin irritation or pruritus 
which spontaneously disappeared in six patients during 
therapy.26
To assess the long-term efficacy and safety of calcitriol, 
an open-label multicenter study of 324 patients with mild-to-
moderate plaque psoriasis were included. They received 
calcitriol 3 µg g-1 ointment twice a day for up to 52 weeks. 
233 of the patients completed 26 weeks and 136 completed 
52 weeks of treatment. Efficacy was demonstrated over the 
course of the treatment assessed with an investigator-rated 
severity score. This evaluation demonstrated no or minimal 
psoriasis symptoms in 11% of the treated patients after 
12 weeks, in 22% after 24 weeks, in 37% after 36 weeks, 
and in 47% after 52 weeks. The psoriasis involved body 
surface area decreased from 16% at the beginning to 11% 
at the endpoints of the study. Serious adverse effects were 
reported in eight patients, all cases probably unrelated to the 
study medication (skin ulcer at distant site, joint disorder, 
two cases of metorrhagia, heart failure, hospitalization due 
to arteriosclerosis, breast cancer, and an infection following 
a dog bite). Ten patients showed transient hypercalcemia 
but none was clinically significant or led to discontinuation 
of the treatment. Furthermore, no clinically significant other 
laboratory test parameters occurred. The global assessment 
of improvement was rated by the patients. After 26 weeks 
53% and after 52 weeks 64% of the patients reported at least 
a marked improvement of their psoriasis while 4% had dis-
continued the treatment due to lack of efficacy and 3% due 
to adverse effects.28
Conclusions: Place of calcitriol 
in therapy of mild-to-moderate 
psoriasis
Twice-daily calcitriol 3 µg g-1 ointment was demonstrated 
to be an effective and safe treatment for mild-to-moderate 
plaque psoriasis,20 including sensitive skin areas.17,26,34 
The same is true for long-term treatment during and up to 
52 weeks.28
For chronic conditions such as psoriasis the availability 
of a range of therapies allows treatment to be adapted to 
patients’ needs, clinical response, and tolerance. It is therefore 
important to determine the comparability and compatibility 
of different treatments and thereby to establish their place in 
the therapeutic armamentarium.
Investigation of the efficacy of twice-daily calcitriol 3 µg g-1 
ointment shows it to be as effective as short contact dithranol, 
a well-established treatment for chronic plaque psoriasis.35 
However, due to the much lower frequency of skin irritation 
and staining, calcitriol was associated with significantly 
better overall patient acceptability than dithranol cream. Clinical, Cosmetic and Investigational Dermatology 2009:2 158
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Topical betamethasone dipropinate, a corticosteroid, was 
demonstrated to be slightly more effective than calcitriol 
3 µg g-1 ointment but a higher proportion of responders 
treated with the latter drug remained in remission over the next 
eight weeks.22 Comparative studies with topical calcipotriol 
50 µg g-1, another vitamin D derivative, showed a tendency 
in favor of calcitriol 3 µg g-1 ointment regarding the efficacy, 
which furthermore had a significantly higher tolerance in 
respect of skin toxicity.24,25 No studies comparing topical 
calcitriol with topical retinoids have been published. In a 
comparison of topical tacrolimus 300 µg g-1, a calcineurin 
antagonist, not approved for treatment of psoriasis but for 
atopic eczema, with calcitriol 3 µg g-1 ointment for the treat-
ment of psoriasis affecting sensitive skin areas like the face 
and the genitofemoral region, the former was demonstrated 
to be more effective and less irritating.27
The effective management of psoriasis frequently 
necessitates combining therapies in order to achieve optimum 
response while minimizing any side-effects. Several studies 
reviewed here show that calcitriol can be safely and effectively 
used in combination with either UVB phototherapy19,21 or a 
topical corticosteroid.23,33 In these studies the combination 
therapy proved to be at least as efficacious as the comparative 
therapy alone. In the case of phototherapy, the combination with 
calcitriol resulted in a significant reduction in the dose of UV 
radiation needed to produce an equivalent therapeutic response. 
A steroid-sparing effect was achieved by using calcitriol in 
the morning and betamethasone valerate in the evening; this 
combination was as effective as twice-daily betamethasone 
velerate. Therefore, in these studies benefit accrued from the 
combination with calcitriol; by allowing for a reduction in 
dose of the standard therapy, the risk of the adverse effects 
commonly associated with these therapies was decreased.
Many studies indicate that the systemic tolerance of 
calcitriol 3 µg g-1 is good. There was no evidence of clinically 
significant effects on calcium or phosphorus homeostasis 
either for the study populations as whole, or for individual 
patients. Although individual cases of asymptomatic 
hypercalcemia were recorded, they were transient and patients 
were able to continue with their treatment.
In conclusion, these studies provide ample evidence that 
calcitriol 3 µg g-1 ointment is an effective and safe treatment 
in the management and control of mild-to-moderate plaque 
psoriasis.
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